Nano Holdings

Nano Holdings, Inc. is a clinical-stage biotechnology company based in Tokyo, Japan, that specializes in the development of advanced nanomedicines and RNA-based therapeutics. Formerly known as NanoCarrier Co., Ltd., the company utilizes its proprietary micellar nanoparticle technology to enhance the delivery and efficacy of therapeutic agents, including mRNA and small molecules. Its current pipeline features programs such as RUNX1 for the treatment of knee osteoarthritis and TUG1 for glioblastoma, alongside established nanoparticle formulations like NC-6300 for angiosarcoma. In late 2025, the company transitioned to a holding company structure to expand its business into strategic healthcare investments and global partnerships.